Calliditas Therapeutics AB ADR (CALT) Social Stream



Calliditas Therapeutics AB ADR (CALT): $17.79

-0.41 (-2.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CALLIDITAS THERAPEUTICS AB (CALT) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering CALLIDITAS THERAPEUTICS AB.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-19 4 $55 $48 $51.75 $18.935 173.3%
2021-12-15 4 $56 $48 $52 $18.935 174.62%
2021-12-17 4 $59 $52 $55.5 $18.935 193.11%
2022-01-13 4 $62 $55 $58 $18.935 206.31%
2022-02-24 3 $59 $55 $56.666 $18.935 199.27%
2022-11-14 3 $60 $55 $57 $18.935 201.03%
2023-01-03 3 $57 $55 $56 $18.935 195.75%

The Trend in the Analyst Price Target


CALT's average price target has moved down $1 over the prior 33 weeks.

Over the past 45 weeks, CALT's average upside potential has been 238.3%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-02-24 3 59 55 56.666 17.910 216.39%
2022-05-18 3 60 55 57.000 15.990 256.47%
2022-07-24 3 60 55 57.000 18.195 213.27%
2022-11-15 3 57 55 56.000 16.500 239.39%
2023-01-03 3 57 55 56.000 18.110 209.22%

CALT Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 3 0 0 0 0 3

The Trend in the Broker Recommendations


Over the past 13 months, CALT's average broker recommendation rating improved by 0.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • In terms of how CALLIDITAS THERAPEUTICS AB fares relative to all US stocks, note that its variance in analysts' estimates is lower than 37.29% of that group.
  • CALT has a higher number of analysts covering the stock than 90.57% of all US stocks.
  • In terms of how CALLIDITAS THERAPEUTICS AB fares relative to stocks in the small market cap category, note that its average analyst price target is higher than 644.89% of that group.
  • To contextualize these metrics, consider that out of stocks in the small market cap category, CALLIDITAS THERAPEUTICS AB's upside potential (average analyst target price relative to current price) is higher than 454.78% of them.

In the Pharmaceutical Products industry, RNA, GBIO, and RPTX are the three stocks most similar to CALLIDITAS THERAPEUTICS AB regarding the price target and analyst recommendation information presented here.

What is the outlook for CALT? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.604 seconds.